Fig. 7.
Fig. 7. Gel mobility shift assay with a DIG-labeled oligonucleotide probe containing TM RARE. Gel-shift assay was performed as described in Materials and Methods. Lane 1 corresponds to the DIG-labeled TM RARE probe incubated in the absence of nuclear extracts. One microgram of nuclear extracts of OCI-AML3 cells was incubated with the DIG-labeled probe in the absence (lanes 2, 3, and 6 through 11) or in the presence of 16- and 69-fold molar excess amount of unlabeled TM RARE (lanes 4 and 5). Increasing amounts of anti-VDR (lanes 6 through 8) or anti-RARĪ± (lanes 9 through 11) antibody was included in the reaction mixture. The position of the specific complex is indicated by the closed arrow and the supershifted band is indicated by the open arrow.

Gel mobility shift assay with a DIG-labeled oligonucleotide probe containing TM RARE. Gel-shift assay was performed as described in Materials and Methods. Lane 1 corresponds to the DIG-labeled TM RARE probe incubated in the absence of nuclear extracts. One microgram of nuclear extracts of OCI-AML3 cells was incubated with the DIG-labeled probe in the absence (lanes 2, 3, and 6 through 11) or in the presence of 16- and 69-fold molar excess amount of unlabeled TM RARE (lanes 4 and 5). Increasing amounts of anti-VDR (lanes 6 through 8) or anti-RARĪ± (lanes 9 through 11) antibody was included in the reaction mixture. The position of the specific complex is indicated by the closed arrow and the supershifted band is indicated by the open arrow.

Close Modal

or Create an Account

Close Modal
Close Modal